Ultrasound and Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00245869|
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : February 21, 2007
This study intends to assess the ability of contrast-enhanced ultrasound to make the efficacy of chemotherapy in breast cancer precise.
This real-time noninvasive and feasible imaging technique allows us, the investigators at University Hospital Tours, to evaluate early vascular changes of breast tumors during treatment. These vascular changes may precede long-term tumoral regression. Imaging of primary breast lesions may be of value in the prediction of late treatment response.
An ultrasound will be performed before the initiation, and after the second and the last dose of chemotherapy.
To investigate the changes occurring in the vascularization of tumors, we will use an intravascular ultrasound contrast agent SonoVue (sulphur hexafluoride microbubbles).
This agent is a microbubbles preparation that is stable, resistant to pressure, and specifically designed to be used as a contrast agent for ultrasound imaging of angiogenesis.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Procedure: Contrast-enhanced Ultrasound||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Contrast-Enhanced Ultrasound and Neoadjuvant Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response|
|Study Start Date :||March 2004|
|Study Completion Date :||February 2007|
- From contrast-enhanced ultrasound: Enhancement parameters derived from time-intensity curves
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245869
|University Hospital of Tours|
|Tours, France, 37044|
|Study Director:||François Tranquart, PR||Centre d'Innovation Technologique - CHRU Tours|
|Principal Investigator:||Catherine LABBE, MD||CRLCC René Gauducheau 44805 ST HERBLAIN|